INSTILLAGEL

Distinctive syringe design to ease insertion

Ready to use. No assembly needed.

UROSAFETIP®: ROUNDED, SMOOTH, ELONGATED TIP1

INSTILLAGEL®’s special design helps minimize epithelial damage. The innovative UROSAFETIP® tip design helps reduce the risk of injury and supports patient comfort.1

Get step-by-step instructions on how to administer INSTILLAGEL®

Get instructions
Visual of the FARCO®* INSTILLAGEL® pre-filled syringe

FARCO®* pre-filled syringe

Broad flanges help prevent slipping

Rounded, smooth, elongated tip

INSTILLAGEL® is generally well tolerated and effective and may help minimize the risk of urethral mucosal injury.2,3

Minimal bubbles1

Reduced bubble formation during instillation provides uniform coating and does not impair vision during endoscopic procedures.

In the in vitro flow assessment, gel was dispensed from the FARCO®* syringe into glass tubes over a 5-second period†,‡

INSTILLAGEL® SYRINGE

  • Section 1
  • Section 2
  • Section 3
  • Section 4

Application directionGel direction

  • Bubble formation is minimized
  • Bubble formation can occur towards the end of the instillation process

Bubble formation was not evaluated quantitatively. Clinical significance is unknown.

Complete
delivery / minimal
residual gel1

Urethra should be fully coated for optimal preparation and for carrying out the transurethral procedure.

The filling volume of INSTILLAGEL® can be instilled completely.

Got questions about INSTILLAGEL®?

Visit FAQs

Average volume of the male urethra is 10.6 mL

Filling volume of INSTILLAGEL® syringe compared to male urethra

10.6 mL

MALE URETHRA

11 mL

INSTILLAGEL®

For a chlorhexidine-free lubricant, consider JELIDO®

Learn more

INSTILLAGEL® (lidocaine and chlorhexidine gel) is indicated for surface anaesthesia, lubrication, and antisepsis for:2

  • The male and female urethra during cystoscopy
  • Catheterization
  • Exploration by sound and other endourethral operations

for additional safety information and for a link to the Prescribing Information, which discusses:

  • Contraindications in children < 2 years of age and in patients with a known or suspected hypersensitivity to this drug or any component of the formulation.
  • Most serious warnings and precautions regarding: use in urethra only (not for parenteral administration) and immediate systemic hypersensitivity reactions.
  • Other relevant warnings and precautions regarding: use of the lowest effective dose; avoiding contact with eyes and middle ear; familial malignant hyperthermia; carcinogenesis and mutagenesis; excessive hypotensive response; use during early pregnancy (first trimester); and dose reduction in children, debilitated patients, acutely ill patients, and patients with sepsis. Use with caution in patients with: severe shock; sepsis and/or traumatized mucosa at the application site; epilepsy; impaired cardiac conduction; bradycardia; impaired cardiovascular function; impaired hepatic or renal function; and in persons with known drug sensitivities.
  • Conditions of clinical use, adverse reactions, drug interactions, and dosing instructions.

JELIDO® (lidocaine hydrochloride jelly) is indicated for:4

  • Surface anaesthesia and lubrication for:
    • The male and female urethra during cystoscopy, catheterization, exploration by sound, and other endourethral operations;
    • Nasal and pharyngeal cavities in endoscopic procedures such as gastroscopy and bronchoscopy;
    • Proctoscopy and rectoscopy;
    • Tracheal intubation.
  • Symptomatic treatment of pain in connection with cystitis and urethritis.

Consult the Product Monograph for contraindications, warnings, precautions, adverse reactions, drug interactions, dosing, and conditions of clinical use. The Product Monograph is also available by calling 1-888-550-6060.

†Internal diameter 5 mm.
‡The syringe tests were performed in the horizontal position.

References: 1. Data on file. PENDOPHARM®, Division of Pharmascience Inc. 2. INSTILLAGEL® Prescribing Information. PENDOPHARM®, Division of Pharmascience Inc. February 19, 2025. 3. Sperling H, Lümmen G, Rübben H. The use of lubricants in urology. Indications and results. Urologe. [A] 2005;44(6):662–666. 4. JELIDO® Product Monograph. PENDOPHARM®, Division of Pharmascience Inc. February 19, 2026.

PENDOPHARM

INSTILLAGEL is a registered trademark of FARCO-PHARMA GmbH, used under license. JELIDO and UROSAFETIP are registered trademarks of Finchley Research & Development Inc., used under license. PENDOPHARM and its logo are registered trademarks of Finchley Research & Development Inc., used under license. *Registered trademarks are the property of their respective owners. © 2026 PENDOPHARM®. All rights reserved.
Publication date: 29-10-2026

Contact us

For any questions about our products or further information about our company, please do not hesitate to contact us.

INSTILLAGEL® and JELIDO® are available at select specialty pharmacies and by special order at most pharmacy outlets.

6111 Royalmount Avenue, Montreal (Quebec), H4P 2T4, CanadaTelephone+1 (514) 340-5045Fax+1 (866) 926-7654 or +1 (514) 733-9684

MED INFO

Toll-free Telephone: +1 (888) 550-6060
Fax: +1 (514) 340-0164
E-mail: [email protected]

PHARMACOVIGILANCE:

By Telephone: +1 (888) 550-6060
By Fax: +1 (866) 551-1939
By E-mail: [email protected]

For Medical and Scientific Information Services, Adverse Event Report, and Customer Service, please visit our website at https://pendopharm.com/contact/.

INSTILLAGEL® important safety information

Indications and clinical use:

INSTILLAGEL® (lidocaine and chlorhexidine gel) is indicated for surface anaesthesia, lubrication, and antisepsis for:

  • The male and female urethra during cystoscopy
  • Catheterization
  • Exploration by sound and other endourethral operations

Contraindications:

  • INSTILLAGEL® must not be used in children under the age of 2
  • Known or suspected hypersensitivity to local anaesthetics of the amide type, to chlorhexidine or to any ingredient in the formulation (e.g., methylparaben, propylparaben etc.)

Most serious warnings and precautions:

INSTILLAGEL® is for urethral use only: Do not use parenterally.

IMMEDIATE SYSTEMIC HYPERSENSITIVITY REACTIONS INCLUDING HYPOTENSION, TACHYCARDIA, SHORTNESS OF BREATH, SKIN ERYTHEMA, AND ANAPHYLAXIS: IN INDIVIDUALS WHO RECEIVED CHLORHEXIDINE GLUCONATE PREPARATIONS APPLIED TOPICALLY TO THE SKIN OR GIVEN INTRAURETHRALLY, INTRANASALLY, OR ON CENTRAL VENOUS CATHETERS IMPREGNATED WITH THE DRUG. DISCONTINUE TREATMENT IMMEDIATELY IF ADVERSE REACTIONS OR HYPERSENSITIVITY OCCUR.

Other relevant warnings and precautions:

  • The lowest dosage that results in effective anaesthesia should be used to avoid high plasma levels and serious adverse effects
  • Avoid contact with eyes and middle ear
  • Potential triggering agent for familial malignant hyperthermia
  • Carcinogenesis and mutagenesis
  • Lidocaine should be used with caution in patients in severe shock
  • Caution in:
    • Patients with sepsis and/or traumatized mucosa at the area of application
    • Patients with epilepsy, impaired cardiac conduction, bradycardia, impaired hepatic or renal function
    • Patients with impaired cardiovascular function
    • Persons with known drug sensitivities
  • Excessive hypotensive response may occur in the presence of severe damage to the urethra
  • Not recommended for use in the first 3 months of pregnancy
  • Reduced doses in children, debilitated patients, acutely ill patients, and patients with sepsis

For more information:

Consult the Prescribing Information for important information relating to adverse events, drug interactions, and dosing information that has not been discussed in this piece. The Prescribing Information is also available by calling 1-888-550-6060.